Elder Pharmaceuticals Ltd Stock Analysis

BSE: 532322 | NSE: ELDERPHARM | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

DeciZen - Make an Informed Decision on Elder Pharma

M-Cap below 100cr DeciZen not available


1. Is Elder Pharmaceuticals Ltd. a good quality company?

Data is not available for this company.

2. Is Elder Pharmaceuticals Ltd. undervalued or overvalued?

No data found

3. Is Elder Pharmaceuticals Ltd. a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Elder Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Elder Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide

ROCE % 9.9%11.9%12.6%13.3%10.1%10.2%9.9%10.3%11.1%-3.6%-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 285355449551620703839985986483233
YoY Gr. Rt. %-24.4%26.6%22.7%12.5%13.4%19.3%17.4%0.2%-51%-
Adj EPS 1221.128.436.627.431.
YoY Gr. Rt. %-75.7%35%28.6%-25.2%14.2%15.9%19.3%-12.9%-413.1%-
BVPS (₹) 124.2146.3172.8203.9220.2251.7297.6336.8303382.5299.2
Adj Net Profit 19.236.852.868.851.658.974.388.677.3-242-62
Cash Flow from Ops. -10.3-5.370.9-37.462.28.961.819.5-25.51,153-
Debt/CF from Ops. -12.8-37.63.3-9.16.462.212.145.4-35.70.5-


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 6%-4.9%-16.8%-51%
Adj EPS -228.9%-233.9%-248.2%-413.1%
BVPS 13.311.78.726.3
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % 12.616.118.219.412.913.213.713.613.1-30.9-8.9
Op. Profit Mgn % 14.717.117.419.116.318.42120.621.8-13.4-95.3
Net Profit Mgn % 6.710.411.812.
Debt to Equity
Working Cap Days 2612432312122322502572813277550
Cash Conv. Cycle 1481431321091171321371471221790

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Elder Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) -30.2 -38.9
TTM Sales (₹ Cr.) 233 631
BVPS (₹.) 299.2 319.6
Reserves (₹ Cr.) 594 636
P/BV 0.13 0.12
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 37.10 / 38.00
All Time Low / High (₹) 20.35 / 474.00
Market Cap (₹ Cr.) 78
Equity (₹ Cr.) 20.5
Face Value (₹) 10
Industry PE 36.9

Management X-Ray of Elder Pharma :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *99.4299.1795.3091.4989.9477.7377.5685.0684.7384.69
* Pledged shares as % of Promoter's holding (%)

Event Update

Analyst's Notes


About Elder Pharmaceuticals Ltd

Elder Pharmaceuticals was incorporated in the year 1983 and commenced operations in 1989. The company is engaged into manufacturing and marketing of prescription pharmaceutical brands, surgical and medical devices.

Elder is one the leading companies in the pharmaceutical formulation market in India. It holds market leader position in three therapeutic segments - Women’s Healthcare, Wound Care and Nutraceuticals.


Elder manufactures API and formulations spread across 4 manufacturing plants in India and one in Nepal. It manufactures various dosage forms like tablets, capsules, syrups, injectables, topical creams and ointments.

It manufactures wide range of pharmaceutical brands such as Thrive G, Formic, Carnitor, Tanatril, B-long, Cranbe, Bonviva etc.

Company Shelcal brand is one of the top brands in the Indian pharmaceutical industry.


The company was awarded Amity Corporate Excellence Award for the year 2008

Elder was also honoured Frost & Sullivan Market Leadership Award for its 'Shelcal' brand for the year 2008.

It was among the Forbes list of 'Asia's 200 Best under a billion' over a period of three years.

It has subsidiary namely Elder International FZCO in Dubai, Somerta Holdings Company in Cyprus and Elder Biomeda EDA in Bulgaria.

In 2012 - Joint Managing Director Mr Alok Saxena has been bestowed with “Brand Slam Leadership Award” on 13th Oct, 2012 by Indira Group of Institutes, Pune.
- Elder Pharma is awarded India's Most Admired Nutrition and Neutraceutical Company of the Year 2012
-Elder Pharmaceuticals Limited is awarded with CIO100 Award.
-Elder Pharma join hands with Swedish firm Sterisol AB

Read More Read Less